Intellia Therapeutics (NASDAQ:NTLA) Stock Price Up 10% – Time to Buy?

Intellia Therapeutics, Inc. (NASDAQ:NTLA)’s stock price traded up 10% on Friday . The stock traded as high as $10.69 and last traded at $10.60. 1,050,652 shares changed hands during trading, a decline of 63% from the average session volume of 2,842,250 shares. The stock had previously closed at $9.64.

Analysts Set New Price Targets

A number of equities analysts have issued reports on NTLA shares. William Blair restated a “neutral” rating and set a $14.00 target price on shares of Intellia Therapeutics in a research report on Monday, November 18th. BMO Capital Markets cut their price objective on Intellia Therapeutics from $70.00 to $50.00 and set an “outperform” rating for the company in a research report on Friday, January 10th. Barclays lowered their target price on Intellia Therapeutics from $76.00 to $55.00 and set an “overweight” rating on the stock in a report on Friday, November 8th. The Goldman Sachs Group cut their price target on Intellia Therapeutics from $19.00 to $12.00 and set a “neutral” rating for the company in a report on Tuesday, January 14th. Finally, Oppenheimer decreased their price objective on Intellia Therapeutics from $60.00 to $40.00 and set an “outperform” rating on the stock in a research note on Monday, January 13th. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $48.71.

Intellia Therapeutics Stock Up 11.0 %

The firm’s 50 day simple moving average is $11.25 and its 200-day simple moving average is $16.41. The company has a market capitalization of $1.09 billion, a PE ratio of -1.97 and a beta of 1.80.

Insiders Place Their Bets

In other news, CEO John M. Leonard sold 26,807 shares of the business’s stock in a transaction on Friday, January 3rd. The shares were sold at an average price of $12.18, for a total transaction of $326,509.26. Following the transaction, the chief executive officer now directly owns 941,115 shares of the company’s stock, valued at approximately $11,462,780.70. The trade was a 2.77 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders have sold a total of 29,000 shares of company stock worth $352,551 over the last quarter. 3.20% of the stock is owned by corporate insiders.

Institutional Trading of Intellia Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of NTLA. nVerses Capital LLC acquired a new stake in Intellia Therapeutics during the 3rd quarter valued at approximately $142,000. Blue Trust Inc. boosted its stake in shares of Intellia Therapeutics by 182.7% during the 3rd quarter. Blue Trust Inc. now owns 4,189 shares of the company’s stock valued at $94,000 after buying an additional 2,707 shares during the last quarter. Eastern Bank acquired a new stake in shares of Intellia Therapeutics during the third quarter worth approximately $41,000. Hennion & Walsh Asset Management Inc. grew its position in shares of Intellia Therapeutics by 34.7% during the third quarter. Hennion & Walsh Asset Management Inc. now owns 53,721 shares of the company’s stock worth $1,104,000 after buying an additional 13,839 shares in the last quarter. Finally, Values First Advisors Inc. bought a new stake in shares of Intellia Therapeutics in the third quarter worth $54,000. 88.77% of the stock is owned by hedge funds and other institutional investors.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.